Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) saw a large decline in short interest in February. As of February 15th, there was short interest totalling 55,500 shares, a decline of 42.2% from the January 31st total of 96,000 shares. Based on an average daily volume of 64,900 shares, the short-interest ratio is presently 0.9 days. Approximately 3.3% of the company’s stock are sold short.

Hedge Funds Weigh In On Lixte Biotechnology

An institutional investor recently bought a new position in Lixte Biotechnology stock. Atlas Legacy Advisors LLC bought a new position in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 12,707 shares of the company’s stock, valued at approximately $26,000. Atlas Legacy Advisors LLC owned approximately 0.56% of Lixte Biotechnology at the end of the most recent quarter. 5.10% of the stock is owned by hedge funds and other institutional investors.

Lixte Biotechnology Price Performance

Lixte Biotechnology stock traded down $0.10 during mid-day trading on Friday, reaching $1.30. The stock had a trading volume of 38,430 shares, compared to its average volume of 90,078. The company has a market capitalization of $2.92 million, a price-to-earnings ratio of -0.75 and a beta of -0.04. The company has a 50-day moving average price of $2.10 and a two-hundred day moving average price of $1.96. Lixte Biotechnology has a one year low of $1.25 and a one year high of $4.40.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.